Pradžia › Autoimuninės ligos › Ajova
Autoimuninės ligos klinikiniai tyrimai Ajova
7 tyrimai dėl Autoimuninės ligos ieško dalyvių vietose Ajova.
Miestai Ajova
Oficialus tyrimo tekstas (anglų kalba)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- The University of Iowa, Iowa City
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT06722235A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Iowa, Iowa City
Renkami dalyviai1 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-10 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- The University of Iowa, Iowa City
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06948318Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- University of Iowa Hospitals and Clinics, Iowa City
Renkami dalyviai3 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-08-17 · NCT06858319A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- University of Iowa, Iowa City
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-06 · NCT06056297A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Iowa, Iowa City
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-29 · NCT04422912Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.